UCB - Gross Profit On Sales

Stock Price
265.30
Daily Change
-2.90 -1.08%
Monthly
3.59%
Yearly
40.18%
Q1 Forecast
249.19

UCB reported EUR2.46B in Gross Profit on Sales for its fiscal semester ending in December of 2024.





Gross Profit On Sales Change Date
Alcon AG USD 1.46B 70M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
argenx SE USD 1.02B 180.32M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 868M 195M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.21B 186M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Orion EUR 254.2M 5.9M Sep/2025
Recordati EUR 423.85M 34.92M Jun/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 2.46B 520M Dec/2024
Unibail Rodamco EUR 997M 516.9M Dec/2024